MIRM News and Press, Mirum Pharmaceuticals Inc. From 05/22/22

Two new Breakout Stocks for Week 21 with better than 10% short-term upside potential, and two Dow 30 Picks. Average cumulative returns now up to +67.1% YTD. High frequency breakouts continue despite Negative Momentum Gauge® signals, with peak gains in 1 of 4 picks above 10%: SCSC...

The following slide deck was published by Mirum Pharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Mirum Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation

Mirum Pharmaceuticals press release (NASDAQ:MIRM): Q1 GAAP EPS of -$1.17 beats by $0.23. Revenue of $12.89M beats by $4.43M. As of March 31, 2022, Mirum had cash, cash equivalents, restricted cash equivalents, and investments of $239.9 million. For further details see: Mirum Pharmaceuti...

- Total revenue for the first quarter of 2022 was $12.9 million including net product revenue for LIVMARLI ® (maralixibat) oral solution of $10.9 million. - Conference call to provide business updates today, May 5 at 5:30 a.m. PT/8:30 a.m. ET Mirum Pharmaceuticals, ...

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter financial results on Thursday, May 5, 2022. That same day, Mirum will host a conference call to discuss the company’s progress and priorities for 2022. Conference call details: Thur...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Value has outperformed growth by a substantial margin ove...

RemeGen, a Yantai biotech with a deep portfolio of antibody and dual therapies, completed a $410 million IPO on the Shanghai Star Exchange. Nanjing Biosion out-licensed global rights (ex-China) to Pyxis Oncology for an immunotherapy aimed at solid tumor cancers in a $226 million agree...

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2021 Earnings Conference Call March 9, 2022 16:30 ET Corporate Participants Ian Clements - Chief Financial Officer Chris Peetz - President, Chief Executive Officer Peter Radovich - Chief Operating Officer Pamela Vig - Chief Scientific Officer Ian Clements...

Mirum Pharmaceuticals press release (NASDAQ:MIRM): Q4 net income of $57.5M Revenue of $3.14M. For further details see: Mirum Pharmaceuticals reports Q4 results

- Strong commercial launch underway with LIVMARLI ® (maralixibat) oral solution; net product revenue of $3.1 million for the first quarter of launch, total 2021 company revenue of $19.1 million - Expect at least $8.0 million in LIVMARLI net product sales in first quarter 20...